Nevertheless, COPZ2 expression was significantly reduced in BLCA (bladder urothelial carcinoma), BRCA (breast invasive carcinoma), CHOL (cholangiocarcinoma), KICH (kidney chromophobe), LUAD (lung adenocarcinoma), PRAD (prostate adenocarcinoma), READ (Rectum adenocarcinoma), STAD (stomach adenocarcinoma), THCA (Thyroid carcinoma), and UCEC (uterine corpus endometrial carcinoma) than in normal controls (Figure 1A). Here, COPZ2 is linked to cholangiocarcinoma.